Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11926366 | 0.88 | GRM4 (0.46) | EPHX2GRM4KDR | |
| SCHEMBL427105 | 0.87 | KDR (0.52) | KMT2AEPHX2GRM4KDR | |
| SCHEMBL11926380 | 0.87 | SETD2 (0.47) | EPHX2GRM4KDR | |
| SCHEMBL11926374 | 0.87 | KDM4E (0.51) | MEN1KMT2AALDH1A1EPHX2GRM4 | |
| SCHEMBL423803 | 0.86 | KDR (0.46) | MEN1KMT2AEPHX2GRM4KDR | |
| SCHEMBL11926369 | 0.86 | GRM4 (0.47) | POLBEPHX2GRM4KDR | |
| SCHEMBL430651 | 0.86 | TSHR (0.56) | MEN1KMT2AALDH1A1POLBGRM4 | |
| SCHEMBL428647 | 0.86 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1EPHX2GRM4 | |
| SCHEMBL11926304 | 0.85 | KDR (0.47) | MEN1KMT2AALDH1A1EPHX2GRM4 | |
| SCHEMBL11926367 | 0.85 | SETD2 (0.45) | MEN1KMT2AALDH1A1EPHX2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | SCN10A 2880/4885SRC 2000/4885MEN1 4796/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | SCN10A 2303/4885SRC 1729/4885MEN1 3751/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | SCN10A 2776/4885SRC 2795/4885MEN1 293/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | SCN10A 2303/4885SRC 1729/4885MEN1 3751/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | SCN10A 2954/4885SRC 1778/4885MEN1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.